Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07328100
NA

Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.

Sponsor: Shanghai 10th People's Hospital

View on ClinicalTrials.gov

Summary

Emerging evidence identifies vascular aging independently predicting cardiovascular events, yet effective clinical interventions remain lacking. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor whose levels decline with age, and preclinical studies suggest that boosting NAD+ can improve vascular function and structure. Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors, such as nicotinamide riboside(NR) or nicotinamide mononucleotide (NMN), can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown. Based on this evidence, the investigator hypothesize that the Coenzyme I for Injection will reverse vascular aging in older adults with established arterial stiffening.

Official title: A Randomized, Double-blind, Parallel Controlled Clinical Trial to Evaluate the Efficacy of Coenzyme I for Injection in the Treatment of Vascular Aging(Pilot Stydy)

Key Details

Gender

All

Age Range

40 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-01-16

Completion Date

2027-12-31

Last Updated

2026-01-08

Healthy Volunteers

No

Interventions

DRUG

Coenzyme I for Injection

Subjects receive 7 consecutive days of intravenous infusion of Coenzyme I for injection.

DRUG

NaCl (placebo)

Subjects receive 7 consecutive days of intravenous infusion of NaCl(0.9%).

Locations (1)

Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, China